A urinary biomarker‐based risk score correlates with multiparametric MRI for prostate cancer detection

Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non‐invasive techniques for the detection of clinically significant disease, leading to a reduction of over‐diagnosis and over‐treatment. The aim of this study was to determine the association between a novel urinary biomarker‐based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection.

[1]  Geert Trooskens,et al.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.

[2]  A. Rosenkrantz,et al.  Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results , 2016, BJU international.

[3]  A. Veltri,et al.  In‐parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance , 2016, BJU international.

[4]  J. Hugosson,et al.  Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. , 2016, European urology.

[5]  P. Pinto,et al.  Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. , 2016, Future oncology.

[6]  S. Taneja.  Re: Prostate Cancer Detection with Magnetic Resonance-Ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies. , 2016, The Journal of urology.

[7]  G. Cattaneo,et al.  High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI‐RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software‐based targeted prostate biopsy after a previous negative standard biopsy , 2016, BJU international.

[8]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[9]  K. Nikolaou,et al.  Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer , 2016, World Journal of Urology.

[10]  J. Fütterer,et al.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.

[11]  T. D. de Reijke,et al.  Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer , 2015, Clinical Cancer Research.

[12]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Papotti,et al.  The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? , 2014, The Journal of urology.

[14]  Ruth Etzioni,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.

[15]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[16]  J. Futterer,et al.  Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI , 2013, International journal of molecular sciences.

[17]  Jennifer L. Beebe-Dimmer,et al.  Prognostic Gleason grade grouping : data based on the modified Gleason scoring system , 2013 .

[18]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[19]  A. Haese*,et al.  The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? , 2010, BJU international.

[20]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[21]  J. Schalken,et al.  New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. , 2003, Urology.

[22]  P. Malone,et al.  Prostate , 1995 .